Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pSLQ5079_pHR_PGK_sfGFP_CoV-F1 Citations (1)

Originally described in: Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29.
PubMed Journal

Articles Citing pSLQ5079_pHR_PGK_sfGFP_CoV-F1

Articles
Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms. Tian S, Liu Y, Appleton E, Wang H, Church GM, Dong M. Cell Rep. 2022 Mar 8;38(10):110476. doi: 10.1016/j.celrep.2022.110476. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.